1ST Biotherapeutics, Inc. (1ST Bio), a private Korean biotech company, and Neuraly Inc., a startup from Johns Hopkins School of Medicine, today announced a collaboration to co-develop novel brain penetrant c-Abl inhibitors for Parkinson’s disease. Recent research has shown that inhibitors to c-Abl could slow the progression of Parkinson’s disease. Parkinson’s disease, a chronic and progressive movement disorder, is the second most common neurodegenerative disease, affecting nearly one million people in the United States.
{iframe}https://www.biosciencetechnology.com/news/2017/10/johns-hopkins-startup-and-korean-biotech-collaborate-parkinsons-drug{/iframe}